Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRT plus lenvatinib and sintilimab for unresectable intrahepatic cholangiocarcinoma
ChiCTR2500105573Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and sintilimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Objective response rate (ORR). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
lenvatinibsintilimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2500105573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105573.